Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
Viscosupplementation (VS) is a symptomatic treatment for knee and other joint osteoarthritis (OA). Despite a long history of use, conflicting opinions remain on the best clinical indications and the most appropriate patients to be treated with intra-articular hyaluronic acid (IA-HA), the optimal dos...
| Autores: | ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Tipo de documento: | Artículo |
| Estado: | Published version |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universitat Pompeu Fabra |
| Repositorio: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:repositori.upf.edu:10230/53631 |
| Acceso en línea: | http://hdl.handle.net/10230/53631 http://dx.doi.org/10.1177/1759720X211018605 |
| Nivel de acceso: | Acceso abierto |
| Palabra clave: | EUROVISCO Hip Hyaluronic acid Intra-articular injection Knee Osteoarthritis Recommendations Viscosupplementation |
| _version_ | 1878737981696638976 |
|---|---|
| author | Conrozier, Thierry |
| author2 | Raman, Raghu Chevalier, Xavier Henrotin, Yves Monfort Faure, Jorge Diraçoglù, Demirhan Bard, Hervé Baron, Dominique Jerosch, Jörg Richette, Pascal Migliore, Alberto |
| author2_role | author author author author author author author author author author |
| author_browse | Bard, Hervé Baron, Dominique Chevalier, Xavier Conrozier, Thierry Diraçoglù, Demirhan Henrotin, Yves Jerosch, Jörg Migliore, Alberto Monfort Faure, Jorge Raman, Raghu Richette, Pascal |
| author_facet | Conrozier, Thierry Raman, Raghu Chevalier, Xavier Henrotin, Yves Monfort Faure, Jorge Diraçoglù, Demirhan Bard, Hervé Baron, Dominique Jerosch, Jörg Richette, Pascal Migliore, Alberto |
| author_role | author |
| collection | Repositorio Digital de la UPF |
| description | Viscosupplementation (VS) is a symptomatic treatment for knee and other joint osteoarthritis (OA). Despite a long history of use, conflicting opinions remain on the best clinical indications and the most appropriate patients to be treated with intra-articular hyaluronic acid (IA-HA), the optimal dosing regimen and the modalities of retreatment. A multidisciplinary committee of European experts on OA (EUROVISCO) was constituted to formulate recommendations, aimed at helping physicians in the decision-making and the optimal achievement of VS. Before each session members were tasked to collate an exhaustive literature review. Level of evidence and strength of recommendation were based on the level of agreement for each item according to the Delphi method. In 2015, a consensus position was proposed for 24 statements. Among those that obtained a consensual agreement, the working group stressed that VS is effective in mild/moderate knee OA but is not an alternative to surgery in advanced OA, and that dosing regimen must be supported by controlled trials. In 2018, two decision algorithms for the retreatment with IA-HA in knee OA were published. Among the key recommendations, the experts recommended to re-treat every year patients with high risk of OA progression, even if not symptomatic. In 2020, EUROVISCO published two sets of recommendations for the design of clinical trials on the disease-modifying effect of VS and for optimizing the results of VS. The working group underlined that an accurate analysis of radiological features and symptoms and a careful clinical examination may improve the chances of success of VS, as well as good technique of injection and the use of imaging guidance. Based on the exhaustive analysis of the literature and their own clinical experience, the EUROVISCO experts offer a wide range of recommendations intended to help practitioners, particularly in certain cases where the specific characteristics of the patients make the therapeutic decision difficult. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_a7e3f61ba01eb81ddbf1114f33a0fe40 |
| institution | Universitat Pompeu Fabra |
| instname_str | Universitat Pompeu Fabra |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:repositori.upf.edu:10230/53631 |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher | SAGE Publications |
| publisherStr | SAGE Publications |
| reponame_str | Repositorio Digital de la UPF |
| spelling | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group Conrozier, Thierry Raman, Raghu Chevalier, Xavier Henrotin, Yves Monfort Faure, Jorge Diraçoglù, Demirhan Bard, Hervé Baron, Dominique Jerosch, Jörg Richette, Pascal Migliore, Alberto EUROVISCO Hip Hyaluronic acid Intra-articular injection Knee Osteoarthritis Recommendations Viscosupplementation Viscosupplementation (VS) is a symptomatic treatment for knee and other joint osteoarthritis (OA). Despite a long history of use, conflicting opinions remain on the best clinical indications and the most appropriate patients to be treated with intra-articular hyaluronic acid (IA-HA), the optimal dosing regimen and the modalities of retreatment. A multidisciplinary committee of European experts on OA (EUROVISCO) was constituted to formulate recommendations, aimed at helping physicians in the decision-making and the optimal achievement of VS. Before each session members were tasked to collate an exhaustive literature review. Level of evidence and strength of recommendation were based on the level of agreement for each item according to the Delphi method. In 2015, a consensus position was proposed for 24 statements. Among those that obtained a consensual agreement, the working group stressed that VS is effective in mild/moderate knee OA but is not an alternative to surgery in advanced OA, and that dosing regimen must be supported by controlled trials. In 2018, two decision algorithms for the retreatment with IA-HA in knee OA were published. Among the key recommendations, the experts recommended to re-treat every year patients with high risk of OA progression, even if not symptomatic. In 2020, EUROVISCO published two sets of recommendations for the design of clinical trials on the disease-modifying effect of VS and for optimizing the results of VS. The working group underlined that an accurate analysis of radiological features and symptoms and a careful clinical examination may improve the chances of success of VS, as well as good technique of injection and the use of imaging guidance. Based on the exhaustive analysis of the literature and their own clinical experience, the EUROVISCO experts offer a wide range of recommendations intended to help practitioners, particularly in certain cases where the specific characteristics of the patients make the therapeutic decision difficult. SAGE Publications http://hdl.handle.net/10230/53631 http://dx.doi.org/10.1177/1759720X211018605 |
| spellingShingle | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group Conrozier, Thierry EUROVISCO Hip Hyaluronic acid Intra-articular injection Knee Osteoarthritis Recommendations Viscosupplementation |
| status_str | publishedVersion |
| title | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group |
| title_full | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group |
| title_fullStr | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group |
| title_full_unstemmed | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group |
| title_short | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group |
| title_sort | Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group |
| topic | EUROVISCO Hip Hyaluronic acid Intra-articular injection Knee Osteoarthritis Recommendations Viscosupplementation |
| topic_facet | EUROVISCO Hip Hyaluronic acid Intra-articular injection Knee Osteoarthritis Recommendations Viscosupplementation |
| url | http://hdl.handle.net/10230/53631 http://dx.doi.org/10.1177/1759720X211018605 |